Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia

A. Rambaldi, F. Huguet, P. Zak, P. Cannell, Q. Tran, J. Franklin, MS. Topp

. 2020 ; 4 (7) : 1518-1525. [pub] 20200414

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020635

In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), overall survival (OS) following blinatumomab, a BiTE (bispecific T-cell engager) immunooncology therapy, was significantly improved vs chemotherapy following induction (cycles 1 to 2). Here we report the efficacy and safety of those who received additional cycles of blinatumomab. Blinatumomab was administered as a continuous IV infusion for 4 weeks in a 6-week cycle. Patients who achieved a bone marrow response (≤5% blasts) or complete remission (full, partial, or incomplete hematological recovery) during induction could receive additional cycles of blinatumomab. OS and relapse-free survival (RFS) for consolidation (cycles 3 to 5) vs no consolidation, and maintenance (cycles ≥6) vs no maintenance were analyzed using Simon-Makuch and Mantel-Byar odds ratios. Of 267 patients who received blinatumomab induction, 86 (32%) entered consolidation and 36 (13%) entered maintenance. Evidence of longer OS was demonstrated among the maintenance group compared with no-maintenance (median OS [95% confidence interval, CI]: not reached for maintenance vs 15.5 months for no maintenance). Median RFS (months; 95% CI) was numerically longer among maintenance group (14.5; 7.1 to 21.9) compared with no-maintenance (9.8; 8.5 to 11.1). A lower incidence of adverse events was seen during maintenance (72.2%) compared with induction (97.2%) and consolidation (86.1%). Adults with R/R ALL who achieved remission following blinatumomab induction had longer survival on continuation therapy than those who discontinued blinatumomab early, supporting the use of blinatumomab as long-term therapy. No new safety signals were reported. This trial was registered at www.clinicaltrials.gov as #NCT02013167.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020635
003      
CZ-PrNML
005      
20240516121528.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2019000874 $2 doi
035    __
$a (PubMed)32289160
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rambaldi, Alessandro $u Università Statale di Milano, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy $7 xx0317376
245    10
$a Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia / $c A. Rambaldi, F. Huguet, P. Zak, P. Cannell, Q. Tran, J. Franklin, MS. Topp
520    9_
$a In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), overall survival (OS) following blinatumomab, a BiTE (bispecific T-cell engager) immunooncology therapy, was significantly improved vs chemotherapy following induction (cycles 1 to 2). Here we report the efficacy and safety of those who received additional cycles of blinatumomab. Blinatumomab was administered as a continuous IV infusion for 4 weeks in a 6-week cycle. Patients who achieved a bone marrow response (≤5% blasts) or complete remission (full, partial, or incomplete hematological recovery) during induction could receive additional cycles of blinatumomab. OS and relapse-free survival (RFS) for consolidation (cycles 3 to 5) vs no consolidation, and maintenance (cycles ≥6) vs no maintenance were analyzed using Simon-Makuch and Mantel-Byar odds ratios. Of 267 patients who received blinatumomab induction, 86 (32%) entered consolidation and 36 (13%) entered maintenance. Evidence of longer OS was demonstrated among the maintenance group compared with no-maintenance (median OS [95% confidence interval, CI]: not reached for maintenance vs 15.5 months for no maintenance). Median RFS (months; 95% CI) was numerically longer among maintenance group (14.5; 7.1 to 21.9) compared with no-maintenance (9.8; 8.5 to 11.1). A lower incidence of adverse events was seen during maintenance (72.2%) compared with induction (97.2%) and consolidation (86.1%). Adults with R/R ALL who achieved remission following blinatumomab induction had longer survival on continuation therapy than those who discontinued blinatumomab early, supporting the use of blinatumomab as long-term therapy. No new safety signals were reported. This trial was registered at www.clinicaltrials.gov as #NCT02013167.
650    _2
$a dospělí $7 D000328
650    12
$a protilátky bispecifické $x terapeutické užití $7 D018033
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a konsolidační chemoterapie $7 D060830
650    _2
$a lidé $7 D006801
650    12
$a akutní lymfatická leukemie $x farmakoterapie $7 D054198
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Huguet, Francoise $u Institut Universitaire du Cancer, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
700    1_
$a Zak, Pavel $u Fakultni Nemocnice Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Cannell, Paul $u Fiona Stanley Hospital, Perth, Australia
700    1_
$a Tran, Qui $u Amgen Inc, Thousand Oaks, CA; and
700    1_
$a Franklin, Janet $u Amgen Inc, Thousand Oaks, CA; and
700    1_
$a Topp, Max S $u Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 4, č. 7 (2020), s. 1518-1525
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32289160 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20240516121522 $b ABA008
999    __
$a ok $b bmc $g 1691248 $s 1141081
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 4 $c 7 $d 1518-1525 $e 20200414 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options